In the last decade, pharmaceutical companies have largely abandoned their male contraceptive development programs. Large Phase 3 pivotal studies to further demonstrate safety and contraceptive efficacy are needed for regulatory approval and will require involvement of the pharmaceutical industry. Engaging pharmaceutical companies to co-develop products and initiate new pathways to product development is critical to moving the field forward.

In the last decade, pharmaceutical companies have largely abandoned their male contraceptive development programs. The article says that bringing male hormonal contraception to market will require pharmaceutical industry involvement, including large Phase 3 studies for regulatory approval.

This is a direct reflection of the fact that the majority of marketed contraceptive methods are also designed for women, while novel male contraceptive technologies are still in development. As reproductive health is not a priority for most major pharmaceutical companies, the onus lies on the donor and social sector investment communities to lead by example and take action to expand efforts to develop MPTs and the novel contraceptive methods that support them. While the lack of pharmaceutical investment is the most discussed financial barrier for the development of male contraceptives and MPTs, the current R&D model conflicts with the MPT and contraceptive sectors even earlier in the product development process.

Eppin Pharma is an emerging pharmaceutical company focused on the development of a safe, non-hormonal male contraceptive that can be taken orally. The company's product is a male contraceptive pill that targets a protein on the surface of sperm, inhibiting their ability to fertilize an egg. Eppin Pharma has received Small Business Innovation Research (SBIR) funding to support the development of this male contraceptive technology.

In the early 2000s, multinational pharmaceutical companies (e.g., Wyeth, Schering, Organon, Merck) abandoned their male contraceptive research and development efforts. Historically, the lack of commercial investment in male contraceptives has been attributed to a perceived lack of demand among men and their partners. Our results suggest that there is considerable potential demand for male contraceptive methods, which may inform future investment decisions by pharmaceutical companies and other stakeholders.

The article says that one of the biggest obstacles to male contraceptives has been the lack of interest and involvement from pharmaceutical companies. It also says the work struggles forward with little or no support from the pharmaceutical industry.

The article states that while the pharmaceutical industry previously supported male contraceptive research and development, industry partners are only spectators in the current phase of the field. This supports the claim that active industry promotion has been limited in recent years.

Discussing why no male pill is on the market, the article quotes Dr. Isabel M. Silva Reus: "Drug companies have also shown a sexist bias and have focused on women because if female contraception works, why research male contraception?" It notes: "To date, no male oral contraceptives or pills are commercially available," despite decades of research. This commentary frames pharmaceutical companies as having prioritized female methods and not significantly advancing or marketing male contraceptive pills yet.

Male Contraceptive Initiative provides funding and advocacy support for the research and development of new methods of non-hormonal, reversible male birth control. Our funding supports young researchers, academic labs, startups, and pharmaceutical companies through grants and equity investments. By reinvesting returns from our equity investments, we create a sustainable funding model that fuels continued innovation in the field of male birth control drug development.

Durham pharmaceutical company Eppin Pharma has secured a new investment that moves the company closer to starting clinical trials for its male contraceptive pill. The Male Contraceptive Initiative, a national nonprofit based in Durham, is investing up to $800,000 to establish a proof of concept for the safety and feasibility of Eppin’s short-term, reversible, non-hormonal oral male contraceptive. Eppin received a $75,000 Small Business Research Loan from the North Carolina Biotechnology Center in 2019 and a $225,000 grant from the National Institutes of Health in 2020.

Male Contraceptive Initiative (MCI), a 501(c)(3) non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide funding to advance the development of a novel, non-hormonal male contraceptive pill. Since 2017, MCI has committed over $5 million USD to support male contraceptive research and development. These investments are often directed toward smaller or emerging pharmaceutical companies and academic groups working on male-controlled contraception.

Reporting on an experimental sAC inhibitor (TDI-11861), the article explains that this preclinical work led to the creation of a start-up: "Drs. Buck and Levin launched Sacyl Pharmaceuticals with colleague Dr. Gregory Kopf, who serves as the company's chief scientific officer." Dr. Levin is quoted as hoping eventually to hear a man request "the male pill" at a pharmacy, indicating the company’s aim to develop and ultimately market an on-demand male contraceptive. The piece nonetheless makes clear that the drug is at a preclinical stage and not yet promoted as a commercial product.

Male Contraceptive Initiative supports science that moves male contraceptives forward. We support a broad program of research including discovery-stage and pre-clinical studies across the drug and device realms. This opportunity will facilitate the screening of validated male contraceptive targets for small-molecule inhibitors using the DNA-Encoded Chemistry Technology core facilities available in the lab of Dr. Martin Matzuk and Center for Drug Discovery at Baylor College of Medicine.

Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially positioning the company with a first-to-market advantage in the male contraceptive market. The company is developing an injectable hydrogel that blocks sperm flow and is intended to be a long-acting, reversible male contraceptive. The new funding will support Phase III development and eventual commercialisation, indicating growing investor and industry interest in male birth control products.

The article says that efforts toward making new male contraceptives have largely hit dead ends, and that investigators believe side effects and regulatory standards make male methods harder to bring forward. It also notes that a new company was formed to continue development, implying that industry support is not absent but remains limited.

The nonprofit says it provides funding and advocacy support for research and development of novel male contraceptives. Its existence is evidence that non-pharmaceutical funding and advocacy have been important in a field where commercial support has been limited.

The article reports that Contraline is developing a male birth control candidate and has attracted investors, showing that some biotech and investor interest exists. It is relevant as counter-evidence to a blanket claim that pharmaceutical companies do not promote male contraceptives.

This page lists ongoing clinical trials for male contraceptives, including a "Phase 2B combined hormonal gel that men apply daily to the skin of their shoulders," containing Nestorone and Testosterone. The trial is run in collaboration with research institutions and funders such as NICHD and the Population Council rather than major commercial pharma. The broader context of the site emphasizes that non-profit and public funding have been central to male contraceptive R&D, implicitly highlighting the historical absence of large-scale pharmaceutical company promotion.

Biotech company Contraline is advancing its injectable contraceptive, ADAM, into Phase 2 human trials—bringing us closer to a long-lasting, reversible male birth control option. Limited innovation in male contraception reflects decades of underinvestment, not a lack of scientific possibility. Increasing funding and support for male contraceptive R&D is critical to expanding contraceptive choice and promoting gender equity in family planning.

This older but domain-specific article analyzes why pharma has not heavily invested in male hormonal contraception. It reports that industry executives perceived "limited commercial viability" and concerns about "liability and long-term safety" as key deterrents to investing in and marketing male contraceptive products. The study concludes that "pharmaceutical investment in hormonal male contraception has been minimal," tying low promotion to perceived market and risk factors rather than scientific infeasibility.

As of the mid‑2020s, no hormonal male pill or injectable contraceptive from major multinational pharmaceutical companies has reached routine commercial availability; male-controlled options remain primarily condoms, vasectomy, and withdrawal. Research and early-stage promotion of male contraceptives is concentrated in academic labs, nonprofits, and small biotech or specialty pharma firms rather than large, global pharmaceutical companies, which typically allocate contraceptive marketing budgets to female-focused products.

The company says its mission is to design and develop a male birth control option. It also states that male birth control options have traditionally been limited to vasectomy, condoms, and withdrawal, showing ongoing commercial development efforts rather than complete absence of promotion.

The page argues that big pharma companies rarely invest in drugs they cannot expect to make profitable, and that pharmaceutical companies do not have much incentive to risk expensive trials for male contraception. It also notes that some researchers think companies doubt men will buy such products.

The article discusses novel nonhormonal pills and injectable hydrogels in clinical trials, which indicates active development in the field. That evidence is relevant because it suggests the industry is not uniformly absent from male contraceptive research.

The post states that larger pharmaceutical companies were interested in male contraception in the early 2000s, but trial and error with those methods largely stalled. It is useful as a concise historical claim that industry interest existed but waned.